Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy.
about
A multicellular signal transduction network of AGE/RAGE signalingStatins and dilated cardiomyopathy: do we have enough data?Inhibition of NF-κB prevents high glucose-induced proliferation and plasminogen activator inhibitor-1 expression in vascular smooth muscle cells.Fluvastatin inhibits AGE-induced cell proliferation and migration via an ERK5-dependent Nrf2 pathway in vascular smooth muscle cells.The influence of atorvastatin on parameters of inflammation left ventricular function, hospitalizations and mortality in patients with dilated cardiomyopathy--5-year follow-up.Advanced glycation end-products: a common pathway in diabetes and age-related erectile dysfunction.Vasculopathy in the setting of cardiorenal syndrome: roles of protein-bound uremic toxins.Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells.Pioglitazone inhibits high glucose-induced expression of receptor for advanced glycation end products in coronary artery smooth muscle cells.Impairment of human keratinocyte mobility and proliferation by advanced glycation end products-modified BSA.Fluvastatin inhibits advanced glycation end products-induced proliferation, migration, and extracellular matrix accumulation in vascular smooth muscle cells by targeting connective tissue growth factor.Efficacy of Subgingivally Delivered 1.2% Atorvastatin in the Treatment of Chronic Periodontitis in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Clinical Trial.A bis-Schiff base of isatin improves methylglyoxal mediated insulin resistance in skeletal muscle cells.The role of autophagy in advanced glycation end product-induced proliferation and migration in rat vascular smooth muscle cells.The Impact of Uremic Toxins on Vascular Smooth Muscle Cell Function.
P2860
Q28704994-C794939D-018B-437E-ABA5-8DA12FC1CFA2Q33787152-8793CD76-6AF2-44EF-AD89-27A513AD2629Q35667264-96316674-6495-45BD-81E6-EC655BB1F3F9Q36380900-46F12AE4-8900-4001-BD2D-F1C76961F23FQ36811609-AAA6C5CD-A62D-428E-8B3F-27477E6FFB51Q38118993-42435832-9D0E-469C-B73E-7A4788230C93Q39243739-3393CB6E-60E5-414D-98B4-16DF5976F411Q42145401-7D946A35-7B59-42B0-8A24-9CDCAC64B34AQ43159153-7FAACA87-AECD-4992-B20A-A70A2B4AFD8EQ45953017-32E1B266-3954-4BEE-B720-4BFBBEE4DBF9Q52665657-DD87D75C-45CE-48D1-975B-232EF0157C4AQ53562629-51EA7FAC-5A6B-4CDE-891E-714E3492A6A5Q53811353-58FBC402-D525-4657-94FE-D529081FDCC9Q55330839-7C04E59F-3B39-4854-AAD3-12091F5C52C7Q55515015-07A463DE-BEA5-43F0-B543-2285A2A7BCD2
P2860
Potential role of HMG CoA reductase inhibitor on oxidative stress induced by advanced glycation endproducts in vascular smooth muscle cells of diabetic vasculopathy.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Potential role of HMG CoA redu ...... ells of diabetic vasculopathy.
@en
Potential role of HMG CoA redu ...... ells of diabetic vasculopathy.
@nl
type
label
Potential role of HMG CoA redu ...... ells of diabetic vasculopathy.
@en
Potential role of HMG CoA redu ...... ells of diabetic vasculopathy.
@nl
prefLabel
Potential role of HMG CoA redu ...... ells of diabetic vasculopathy.
@en
Potential role of HMG CoA redu ...... ells of diabetic vasculopathy.
@nl
P2093
P2860
P50
P1476
Potential role of HMG CoA redu ...... cells of diabetic vasculopathy
@en
P2093
Byoung Kwon Lee
Ki-Chul Hwang
Myunghyun Kim
Se-Jung Yoon
Woochul Chang
Young Won Yoon
Young-Ho Lee
P2860
P2888
P304
P356
10.3858/EMM.2009.41.11.086
P577
2009-11-01T00:00:00Z
P5875
P6179
1001864969